Tien Liang Biotech Co

Tien Liang Biotech Co EBIT per Share

The EBIT per Share of Tien Liang Biotech Co (4127.TWO) as of Nov 19, 2026 is -0.35 TWD. In the previous year, EBIT per Share was 0.01 TWD — a change of -2,822.09% (lower).

EBIT per Share

-0.35TWD

YoY

-2,822.09%

Last updated:

EBIT per Share of Tien Liang Biotech Co is 2025 -0.35 TWD. EBIT per Share of Tien Liang Biotech Co was 2024 0.01 TWD. It decreases by -2,822.09% lower compared to the previous year.

The Tien Liang Biotech Co EBIT per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT per Share
Date
EBIT per Share
Jan 1, 2018
-1.42 TWD
Jan 1, 2019
-0.93 TWD
Jan 1, 2020
-1.00 TWD
Jan 1, 2021
1.08 TWD
Jan 1, 2022
1.33 TWD
Jan 1, 2023
0.45 TWD
Jan 1, 2024
0.01 TWD
Jan 1, 2025
-0.35 TWD
The Tien Liang Biotech Co EBIT per Share history
YEAREBIT per ShareYoY
-0.35TWD-2,822.09%
0.01TWD-97.20%
0.45TWD-66.00%
1.33TWD+23.05%
1.08TWD-208.58%
-1.00TWD+7.40%
-0.93TWD-34.69%
-1.42TWD-66.71%
-4.27TWD+506.16%
-0.70TWD-144.05%
1.60TWD-11.95%
1.82TWD+10.01%
1.65TWD+12.51%
1.47TWD+358.50%
0.32TWD-205.98%
-0.30TWD-129.72%
1.02TWD-14.65%
1.19TWD+31.93%
0.90TWD-62.45%
2.40TWD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Tien Liang Biotech Co Stock analysis

What does Tien Liang Biotech Co do? Tien Liang BioTech Co. Ltd. manufactures and sells Chinese herbal and western medicine, including active pharmaceutical ingredients (APIs), biopharmaceuticals, and traditional Chinese medicines. The company imports, wholesales, and retails western medicines domestically. Its products are distributed within the domestic market, targeting healthcare providers and consumers seeking traditional and modern pharmaceutical solutions. The firm's revenue streams come from the sale of manufactured medicines, APIs, biopharmaceuticals, and retail distribution of western medicines. Domestic market sales form the core of its business, with no mention of international distribution channels. The company serves both the traditional Chinese medicine segment and the modern pharmaceutical segment through its comprehensive product portfolio. Tien Liang BioTech operates within the pharmaceutical manufacturing and distribution sector, focusing on domestic sales of herbal, western, and biopharmaceutical products. Its business model integrates manufacturing, import, wholesale, and retail operations to serve the local healthcare market. Tien Liang Biotech Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Tien Liang Biotech Co stock

EBIT per Share of Tien Liang Biotech Co is -0.35 TWD in 2025.

EBIT per Share of Tien Liang Biotech Co changed from 0.01 TWD to -0.35 TWD, representing a -2,822.09% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBIT per Share Tien Liang Biotech Co since 2006 – with annual values, charts, and detailed analysis.

EBIT per Share measures operating profit allocated to each outstanding share.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Tien Liang Biotech Co

All Key Metrics — Tien Liang Biotech Co